Skip to main content
Premium Trial:

Request an Annual Quote

RNAi and Huntington's Disease

Alnylam and Medtronic are working together to develop RNA interference as a treatment for Huntington's disease, reports The Wall Street Journal. Medtronic is working the task of creating a pump and catheter system to deliver Alnylam's therapy to the right spot of the brain "without hiking up cranial pressure too much and damaging brain tissue," the Journal adds. Alnylam is using an siRNA to block mRNA. "What we do is shut off the spigot," Alnylam president Barry Greene says. "We stop the creation of a protein."

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.